4//SEC Filing
Landry Robert E 4
Accession 0001968202-24-000040
CIK 0000872589other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 4:17 PM ET
Size
13.5 KB
Accession
0001968202-24-000040
Insider Transaction Report
Form 4
Landry Robert E
SVP Fin, Dep CFO
Transactions
- Tax Payment
Common Stock
2024-01-23$948.50/sh−776$736,036→ 23,308 total - Exercise/Conversion
Common Stock
2024-01-24$378.98/sh+500$189,490→ 23,808 total - Tax Payment
Common Stock
2024-01-24$951.26/sh−352$334,844→ 23,456 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-23−1,100→ 13,087 totalExercise: $378.98Exp: 2027-12-12→ Common Stock (1,100 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-24−500→ 12,587 totalExercise: $378.98Exp: 2027-12-12→ Common Stock (500 underlying) - Exercise/Conversion
Common Stock
2024-01-23$378.98/sh+1,100$416,878→ 24,084 total
Holdings
- 270(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001585160
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 4:17 PM ET
- Size
- 13.5 KB